GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical studies without systematic review methodology.
PubMed 42311464 · doi:10.2147/DDDT.S613616
What was done
The authors synthesized preclinical and clinical evidence regarding the repurposing of glucagon-like peptide-1 receptor agonists (GLP-1RAs) across multiple neurological conditions, including Alzheimer's disease, Parkinson's disease, stroke, intracerebral hemorrhage, Huntington's disease, multiple sclerosis, ALS, depression, epilepsy, and spinal cord injury. They summarized molecular mechanisms and addressed translational barriers.
What was found
No quantitative findings or numerical outcomes are reported in the abstract. Preclinical models demonstrated activation of cAMP/PKA/CREB and PI3K/Akt pathways, suppression of GSK-3β and NLRP3 inflammasomes, and enhanced AMPK-dependent autophagy/mitochondrial biogenesis, leading to reduced protein aggregation and neuronal loss. Clinical results were reported as mixed, with some trials showing modest cognitive or motor gains and others finding no significant effect on disease progression.
Why it matters
The paper frames the translational gap between robust animal neuroprotection and inconsistent clinical trial results, emphasizing that differential blood-brain barrier permeability among GLP-1RAs may explain conflicting outcomes.
Limits
The review is narrative rather than systematic, with no formal search protocol, meta-analytic data, or quality assessment of included studies. The abstract provides no quantitative clinical data or sample sizes, and much of the underlying evidence rests on animal models.
Cited by
- supports GLP-1 receptor agonists have anti-inflammatory effects on joints and the brain.